(RTTNews) - Mersana Therapeutics (MRSN) announced the FDA recently granted an additional Fast Track designation to XMT-1660. The new Fast Track designation is for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or HER2-negative disease. The company also announced that the World Health Organization has approved emiltatug ledadotin as XMT-1660s international nonproprietary name.
Separately, Mersana Therapeutics announced positive initial clinical data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin, Mersanas lead Dolasynthen ADC candidate targeting B7-H4.
"We believe the initial safety, tolerability and efficacy data for Emi-Le demonstrate a profile that is exciting and differentiated within both the B7-H4 field and the broader ADC landscape, said Martin Huber, CEO of Mersana Therapeutics.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
